XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Full Enrollment of Phase 3 4WARD Trial Expected in 2H25 X4 ...

Q4 2024 Earnings Call Transcript March 25, 2025 X4 Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0 ...

X4 Pharmaceuticals Inc (XFOR) navigates a challenging landscape with strategic cost reductions and promising product ...

In the assessment of 12-month price targets, analysts unveil insights for X4 Pharmaceuticals, presenting an average target of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Get Our Latest Stock Analysis on XFOR X4 Pharmaceuticals Stock Performance XFOR opened at $0.25 on Friday. X4 Pharmaceuticals has a twelve month low of $0.24 and a twelve month high of $1.60. The ...

Shares of XFOR stock opened at $0.31 on Friday. The stock has a market capitalization of $52.41 million, a P/E ratio of -3.41 and a beta of 0.39. The company has a current ratio of 4.89 ...

Mark Baldry, the Chief Commercial Officer of $XFOR, bought 13,404 shares of the company on 11-15-2024 for an estimated $4,597. This trade was reported by Quiver ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on X4 Pharmaceuticals (XFOR – Research Report) and ...

BOSTON (AP) — BOSTON (AP) — X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $39.8 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of 20 ...

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.